Efficacy of Combination Therapy of Lenvatinib and New FP for the Treatment of Unresectable Advanced Hepatocellular Carcinoma: A Case Report
Author:
Affiliation:
1. Department of Gastroenterology, Saitama Red Cross Hospital
2. Chiba Chuo Clinic
3. Department of Gastroenterology, Tokyo Women's Medical University Yachiyo Medical Center
Publisher
Japan Society of Hepatology
Link
https://www.jstage.jst.go.jp/article/kanzo/65/9/65_460/_pdf
Reference8 articles.
1. 1) Ikeda M, Yamashita T, Ogasawara S, et al. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD. Liver Cancer 2024; 13 (2): 193-202
2. 2) Kudo M, Ueshima K, Saeki I, et al. A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial. Liver Cancer 2024; 13 (1): 99-112 doi: 10.1159/000531377, Liver Cancer 2023. Published online: June 5, 2023
3. 3) Ueshima K, Komemushi A, Aramaki T, et al. Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment. Liver Cancer 2022; 11 (5): 407-425
4. 4) Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 2018; 3: 424-432
5. 5) Niizeki T, Sumie S, Torimura T, et al. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol 2012; 47 (6): 686-695
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3